Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HHAT | Q5VTY9 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297284 | 1.00 | POLB (0.56) | POLBTACR1MC4RHTTMEN1 | |
| SCHEMBL830668 | 1.00 | POLB (0.56) | POLBTACR1MC4RHTTMEN1 | |
| SCHEMBL16350188 | 0.90 | POLB (0.56) | POLBTACR1MC4RHTTMEN1 | |
| SCHEMBL5972730 | 0.88 | ITGA4 (0.44) | POLBTACR1MC4RLMNA | |
| SCHEMBL5657809 | 0.88 | ITGA4 (0.44) | POLBTACR1MC4RLMNA | |
| SCHEMBL5657812 | 0.88 | ITGA4 (0.44) | POLBTACR1MC4RLMNA | |
| SCHEMBL20805978 | 0.84 | MC4R (0.51) | POLBMC4RMEN1TSHRKMT2A | |
| SCHEMBL22926184 | 0.84 | MC4R (0.51) | POLBMC4RMEN1TSHRKMT2A | |
| SCHEMBL13853719 | 0.83 | TACR1 (0.44) | POLBTACR1HTTRIPK1SLC6A2 | |
| SCHEMBL7546130 | 0.83 | MC4R (0.41) | POLBTACR1MC4RMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143405-B2 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2077719-B1 | PIPERIDINE AND PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100041667-A1 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME LLC | 2010-02-18 | — | — | US | disclosed |
| EP-2077719-A2 | PIPERIDINE AND PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck and Co., Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008036316-A2 | PIPERIDINE AND PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041667-A1 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | BACE1, BACE2, PSEN1 | POLB 236/4885TACR1 443/4885MC4R 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.